Anthony Bresin has more than 25 years of experience in the industrial biotechnology field, with expertise spanning fermentation, purification, and process scale-up from laboratory to industrial manufacturing.

He holds a Ph.D. in Industrial Fermentation on hyaluronic acid production from Reims Champagne-Ardenne University (France).

From 2000 to 2018, he served at ARD (Agro-Industrie Recherches et Développements, France), where he successively held scientific and managerial positions, ultimately as Chief Scientific Officer and Head of R&D. During this period, he led programs in fermentation, fractionation, and biopolymer development, contributing to the creation and industrialization of new bio-based molecules and polymers.

He then joined HTL (2018–2023) as Chief R&D and Validation Officer, overseeing R&D programs and technology transfers focused on biopolymers such as hyaluronic acid.

Since 2023, he has been leading AnBreiL, a biotechnology advisory firm providing scientific and strategic support in R&D, process development, and scale-up for companies active in biopolymers and fermentation-derived products.

PhD in analytical chemistry with an experience of 15 years in analytical laboratories.

• Strong expertise in analytical chemistry for cosmetic products testing and pharmaceutical or biopharmaceutical products testing
• Expertise in fast alternative methods for microbiological testing
• Knowledge in cosmetic and drug formulation
• Skills in regulatory affairs for cosmetic industry and for the pharmaceutical industry (GMP and submission files)
• Experience of FDA inspections
• Implementation of certifcation ISO 9001, ISO 14001 and OHSAS 18001

Specialties:

• Management of multicompetency teams in the field of analytical chemsitry
• Building collaboration beteween business units worldwide
• Coordination of research work in collaboration with Universities
• Showing a high level of customer focus and integrity
• Ability to work under pressure and team player

Depuis août 2020, Gautier Decock est Directeur de Seqens’lab. Seqens est un acteur mondial intégré de la synthèse pharmaceutique et des ingrédients de spécialité.

Olivier Nore, get a PhD in Chemical and Biochemical Engineering obtained conjointly in the University of Western Ontario (Canada) and ENSIC/INPL Nancy (France). He finalize his formation in Project Management at the MTI of Boston (US).
He spend the major part of his career in the industry. He start his career working in R&D for ELF, followed by Rhone-Poulenc and Rhodia. For Aventis Animal Nutrition, who became Adisseo, he occupied the position of R&D Process Director, and Operation Director for Metabolic Explorer.
Actually Innovation Director, Processes and Biotechnology for AVRIL Group, his mission is to deployed for the Group new innovative technologies.[/caption]

Involved for several years in development and promotion of in vitro toxicology assays based on reconstructed human tissues.

After a PhD in neuroscience at the French National Institute of Health and Medical Research (INSERM) he held a temporary teaching position at the university of Tours (France). He joined L’Oréal R&I in 2000 at the Life Science Research Center where he was involved in development and implementation of computerized tools for alternative to animal approaches in toxicology (results database, expert systems).

In 2004 he was appointed to scientific communication on alternative methods to animal testing and tissue engineering.

In 2011 he joined EPISKIN, a subsidiary of L’Oréal, dedicated to development and production of reconstructed human epithelia. As Scientific Director, he has been involved in several development projects that led to the introduction of new models and methods to the market. He developed the EPISKIN Academy program to promote the dissemination of alternative methods through education and training and to relay EPISKIN commitments to 3Rs.

Involved for several years in biocompatibility of medical devices he is Chairman of the French AFNOR S92J commission and convenior of the WG8 skin irritation and sensitization of the ISO/TC194 for biocompatibility of medical devices. He is also L’Oreal R&I Research associate and member of the advisory council of the Indian Society for Alternatives to Animal Experiments (SAAE)

After an agricultural engineer School in France (Lasalle Beauvais), Alexis RANNOU joined ARD for activities in R&D to extract non digestible sugar for surfactant application (1991-1995). He was after in charge of ARD’s pilot plant (1995-1997).

In 1997 he joined the Soliance company (daughter company of ARD) as technical director.

In 2000 he was named as Deputy General Manager in charge of the industrial production.

In 2007 he was in charge of the innovation team and several global accounts.

In 2014 he joined Givaudan as Operations Director & site manager

Since 2018, he held the position of Head of Operations Strategy in charge of tolling & process development for Givaudan Active Beauty.

André Tordeux est avant tout un entrepreneur. Sa carrière professionnelle, au départ celle d’un universitaire, est jalonnée d’intitiaves, toutes orientées vers le développement. En 1985 il crée un centre de recherche en économie régionale, le CRESC. Peu de temps après, il crée le premier Centre de Valorisation et de Transfert de Technologies intégré à une université (Le CEFE), puis un cabinet Conseil pour le redressement d’entreprises en difficulté (ADRYADE). C’est tout naturellement qu’il deviendra responsable du pôle entrepreneuriat de l’EDHEC en 1996. En créant la société Genoscreen en 2001, André Tordeux quitte son habit de Directeur de Recherche en sciences de gestion pour se lancer dans l’aventure de la génomique. Cet engagement à la direction d’une Biotech, qui figure aujourd’hui parmi les leaders du marché de la biologie moléculaire, en France, lui vaut de sièger au sein des Comités Scientifiques et Conseils de Pôles de compétitivité NSL et AQUIMER et d’être administrateur d’institutions vouées à l’innovation et au développement comme EURASANTE, le CETI (Centre Européen des Textiles Innovants) et ADEBIOTECH.